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Background: Increased production of matrix metalloproteinases (MMPs) is closely related to the progression of
osteoarthritis (OA). The present study was performed to investigate the potential value of biochanin A in inhibition
of MMP expression in both rabbit chondrocytes and an animal model of OA.
Methods: MTT assay was performed to assess chondrocyte survival in monolayers. The mRNA and protein
expression of MMPs (including MMP-1, MMP-3, and MMP-13) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in
interleukin-1 < beta > (IL-1β)-induced rabbit chondrocytes were determined by quantitative real-time PCR and
enzyme-linked immunosorbent assay (ELISA), respectively. The involvement of the NF-kappaB (NF-κB) pathway
activated by IL-1β was determined by western blotting. The in vivo effects of biochanin A were evaluated by
intra-articular injection in an experimental OA rabbit model induced by anterior cruciate ligament transection
(ACLT).
Results: Biochanin A downregulated the expression of MMPs and upregulated TIMP-1 at both the mRNA and
protein levels in IL-1β-induced chondrocytes in a dose-dependent manner. In addition, IL-1β-induced activation of
NF-κB was attenuated by biochanin A, as determined by western blotting. Moreover, biochanin A decreased
cartilage degradation as determined by both morphological and histological analyses in vivo.
Conclusions: Taken together, these findings suggest that biochanin A may be a useful agent in the treatment and
prevention of OA.
Keywords: Biochanin A, Osteoarthritis, Chondroprotection, Interleukin-1beta, Matrix metalloproteinases, Anterior
cruciate ligament transection (ACLT)Background
Osteoarthritis (OA) is a multifactorial degenerative joint
disorder characterized by the progressive breakdown of
cartilage extracellular matrix. OA affects approximately
12% of the aging population in western countries, while
a quarter of people aged over 55 have an episode of per-
sistent knee pain [1]. There is still no effective treatment
to block the progression of OA. Other than surgical
therapies, treatment for OA has generally been aimed at
alleviating the major complaints, such as swelling, pain,
and muscle tightness.* Correspondence: liba2013sky@163.com
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unless otherwise stated.Homeostasis of the cartilage is maintained by the bal-
ance between the anabolic and catabolic activities of the
articular chondrocytes [2]. The aggregating proteoglycan
along with type II collagen provides robust mechanical
properties to cartilage in a healthy joint. Increased type
II collagen breakdown by collagenases and aggrecan
cleavage by aggrecanases ultimately lead to joint cartil-
age destruction and exposure of the underlying bone [3].
The matrix metalloproteinases (MMPs) are thought to
be the key matrix degradation enzymes due to their abil-
ity to cleave most components of the extracellular
matrix [4]. In addition, the imbalance between MMPs
and tissue inhibitors of metalloproteinases (TIMPs) plays
a pathophysiological role in the progression of OA [5].
Inflammatory cytokines, such as interleukin-1 beta (IL-
1β), tumor necrosis factor-alpha (TNF-α), and IL-6, have
been detected in the synovial fluid of OA patients [6].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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OA progression by inducing MMP expression as well as
other catabolic factors [7].
Currently, there is growing interest in compounds ex-
tracted from plants that possess significant value in the
treatment of OA for their potent antiarthritic effects and
minimal side effects. Biochanin A, an isoflavone found
in red clover, has been shown to possess anticancer, anti-
allergic, and anti-inflammatory effects [8]. A recent
study indicated that biochanin A exerted antiprolifera-
tive and anti-inflammatory effects through the inhibition
of iNOS expression, p38-MAPK and ATF-2 phosphoryl-
ation, and blocking of NF-κB nuclear translocation [9].
A previous study indicated that biochanin A inhibited
tumor invasion in human glioblastoma (U87MG) cells
by suppressing the enzymatic activities of MMP-2 and
MMP-9 [10]. As MMPs are regarded as major factors in
the pathophysiology of OA, this close link between bio-
chanin A and MMPs prompted us to explore whether
biochanin A could have a protective effect in OA by
regulating MMPs. The present study was performed to
determine the effects of biochanin A treatment on
osteoarthritis in vitro and in vivo.Methods
Reagents
Biochanin A and 3-(4, 5-Dimethyl-2-thiazolyl)-2, 5-
diphenyl-2H-tetrazolium bromide (MTT) were ob-
tained from Sigma-Aldrich (St Louis, MO, USA).
Recombinatnt interleukin-1beta was purchased from
Peprotech Group (USA). Dul-becco‘s Modified Eagle’s
Medium (DMEM), penicillin and streptomycin, fetal
bovine serum (FBS), 0.05% trypsin and collagenase II were
obtained from GibcoBRL (Grand Island, NY, USA). Bio-
chanin A was dissolved in dimethyl sulphoxide (DMSO)
and filtered prior to use.Isolation and culture of chondrocytes
The study was approved by the Institutional Animal
Care and Use Committee of Zhejiang University
(Hangzhou, China) and conducted in accordance with
the Guide for the Care and Use of Laboratory Animals
as adopted and promulgated by the United States Na-
tional Institutes of Health. Normal articular cartilage
was collected from the tibial plateau and femoral con-
dyle of 4-week-old New Zealand rabbits. Cartilage was
cut into thin slices and digested with 0.4% collagenase II
in DMEM at 37°C for 4 h. The released cells were cen-
trifuged, resuspended, and cultured in 75-cm2 culture
flasks in complete DMEM supplemented with 10% FBS
and antibiotics (100 units/mL penicillin, 100 μg/mL
streptomycin). Confluent primary chondrocytes werepassaged at a ratio of 1:3. Chondrocytes from passages
two to three were used for our experiments.
Assessment of cell viability
The cytotoxicity of biochanin A to rabbit chondrocytes
was evaluated in the presence of increasing concentrations
of biochanin A (0, 5, 25, 50 μM) by using the MTT assay
according to the instructions of the manufacturer as previ-
ously described [11]. Briefly, rabbit chondrocytes were
seeded onto 96-well plates at a density of 5 × 103/well.
Various concentrations of biochanin A (5, 25, 50 μM) was
added to cultured wells and incubated for 24 h. At the
indicated time, 20 μL of MTT solution (5 mg/ml in
phosphate-buffered saline) was added to each well and in-
cubated for another 4 h at 37°C. After removement of
supernatant, 150 μL of DMSO was added to each well and
absorbance at 570 nm was measured using a microplate
reader (Bio-Rad, Hercules, CA, USA).
Quantitative real-time polymerase chain reaction (PCR)
Serum-starved chondrocytes were pretreated with various
concentrations of biochanin A for 2 h followed by co-
incubation with IL-1β for 24 h. At the indicated time, the
monolayer chondrocytes were harvested for extraction of
total RNA by using Trizol Reagent (Invitrogen, Carlsbad,
CA), while the culture supernatant was collected for stor-
ing at −80°C until use. First complementary DNA (cDNA)
was synthesized by using a primescript –RT reagent kit
(TaKaRa Biotechnology Co, Ltd, Japan). Quantitative
real-time PCR was performed in 20 μL reactions by the
following procedures: followed by 40 cycles of 95°C for
15 seconds and 60°C for 32 seconds. The following
primers were used: for MMP-1, 5’-atgctgaaaccctgaa-
gatgat-3’ (forward) and 5’- ccttggagactttggtgaatgt-3’
(reverse); for MMP-3, 5’- cgttcctgatgttggtcactt -3’ (for-
ward) and 5’- tcagcctctccttcatacttcc -3’ (reverse); for
MMP-13, 5’-cccctcctcaacagtaacgag-3’ (forward) and
5’- agtttgcctgtcacctctaagc-3’ (reverse); for TIMP-1,
5’-gggctccagaagtcaatcatac-3’ (forward) and 5’-tacccg-
cagacactttccat-3’ (reverse); for 18S, 5’-cgtagttccgaccata
aacgat-3’ (forward), 5’- aatctgtcaatcctgtccgtgt-3’ (re-
verse). Expression of 18S was used as endogenous
control. Amplification and quantification of relative
expression levels of MMP-1, MMP-3, MMP-13 and
TIMP-1 was determined by ΔΔCT method [12].
ELISA
The effect of IL-1β and/or biochanin A on the level of
MMP-1, MMP-3, MMP-13 and TIMP-1 secreted by
rabbit chondrocytes in the culture supernatant mentioned
above was furthered detected by using commercially avail-
able ELISA kit (R&D Systems, Inc., Minneapolis, MN,
USA) and all the assays were performed in accordance
with the manufacturer’s instructions.
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Confluent rabbit chondrocytes were starved of serum
overnight and pretreated with various concentrations of
biochanin A for 2 h, followed by coincubation with IL-
1β for 24 h. Cells were washed with ice-cold PBS and
lysed with lysis buffer. The protein samples were sepa-
rated by 12% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) and transferred onto PVDF
membranes. The membranes were blocked with 5%
non-fat milk dissolved in TBST buffer and probed with
primary antibodies against MMP-1, MMP-3, MMP-13,
TIMP-1 (Proteintech, Chicago, IL), IκB-α, NF-κB p65,
and β-actin (Cell Signaling Technology, Danvers, MA) at
4°C overnight. The membranes were washed with TBST
and incubated with appropriate HRP-labeled secondary
antibodies for 1 h at room temperature. Detection was car-
ried out using enhanced chemiluminescent (ECL) substrate
and exposure to Kodak X-Omat film (Kodak, Rochester,
NY) according to the manufacturer’s protocols.Animal studies
Rabbits were obtained from the Animal Center of Zhejiang
University and the procedures were approved by the Insti-
tutional Animal Care and Use Committee of Zhejiang Uni-
versity, Hangzhou, China. Twelve mature New Zealand
rabbits underwent bilateral anterior cruciate ligament
transection (ACLT) and divided randomly into the low-
concentration (A) and high-concentration (B) biochanin A
treatment groups. Four weeks after ACLT surgery, rabbits
in groups A and B received an intra-articular injection of
0.3 mL of 5 and 25 μM biochanin A, respectively, into the
left knee and 0.3 mL of DMSO (vehicle) into the right
knee. Weekly administration continued for 5 weeks. All
rabbits were sacrificed after 9 weeks of ACLT surgery.
Four rabbits were used as a normal control group.Histological assessment
Collected specimens of femoral condyle were fixed in
10% neutral-buffered formalin for 72 h. After dehydra-
tion through an alcohol series, specimens were embed-
ded in paraffin, cut into sections 7 μm thick, and stained
with Safranin-O-fast green. The degree of cartilage deg-
radation was scored according to the Mankin system by
two independent researchers in a blinded manner [13].Figure 1 Effects of biochanin A on chondrocytes viability.
Cells were treated with various concentrations of biochanin A for
24 h. The cytotoxicity of biochanin A toward chondrocytes was
assessed by MTT assay.Evaluation of cartilage gene expression by quantitative
real-time PCR
Collected cartilage was frozen in liquid nitrogen prior to
use. The mRNA levels of MMP-1, MMP-3, MMP-13, and
TIMP-1 in all cartilage samples were assessed by quantita-
tive real-time PCR as described above.Statistical analysis
All experiments were performed duplicated and repeated
three times using independent samples. The results are
expressed as means ± standard deviation (SD). One-way
ANOVA followed by Dunnett’s analysis was used for
statistical analysis. In all analyses, P < 0.05 was taken to
indicate statistical significance.
Results
Effects of biochanin A on chondrocytes viability
MTT assay was performed to evaluate the cytotoxicity of
biochanin A on rabbit chondrocytes. As shown in Figure 1,
biochanin A at 5 to 50 μM exhibited no significant cyto-
toxicity toward rabbit chondrocytes.
Effects of biochanin A on gene expression of MMP-1,
−3, −13, and TIMP-1 induced by IL-1β in chondrocytes
Quantitative real-time PCR was performed to assess the
mRNA levels of MMP-1, −3, −13, and TIMP-1 in chon-
drocyte monocultures. As shown in Figure 2, IL-1β en-
hanced the expression of MMP-1, −3, and −13, and
decreased the expression of TIMP-1. In chondrocytes pre-
treated with biochanin A, the upregulated MMP-1, −3,
and −13 expression was markedly inhibited and the down-
regulated TIMP-1 expression was enhanced.
Effects of biochanin A on protein expression of MMP-1,
−3, −13, and TIMP-1
To further investigate MMP and TIMP-1 protein levels in
IL-1β–stimulated chondrocytes, we used enzyme-linked
immunosorbent assay (ELISA) and western blotting. As
shown in Figures 3, 4 and 5, MMP-1, −3, and −13 protein
levels were increased after IL-1β stimulation, and this ef-
fect was markedly suppressed by biochanin A in a dose-
dependent manner. Although 5 μM biochanin A showed
no significant effects, a higher concentration of biochanin
A markedly suppressed the production of MMP-1, −3,
Figure 2 Relative gene expression of MMP-1, −3, −13 and TIMP-1 in IL-1β -induced chondrocytes. Cells were pre-treated with different
concentrations of biochanin A for 2 h, followed by co-incubation with IL-1β (10 ng/ml) for 24 h. Data were expressed as means ± standard
deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001, compared with cells stimulated with IL-1β alone; # P < 0.01, compared with normal
chondrocytes. (a), (b), (c), (d) represented as the relative gene expression of MMP-1,MMP-3,MMP-13 and TIMP-1 respectively.
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sistent with the quantitative real-time PCR results.
Effects of biochanin A on IκB-α degradation and NF-κB ac-
tivation in IL-1β-treated chondrocytes
In the present study, we assayed IκB-α and NF-κB p65
to evaluate the involvement of the NF-κB pathways acti-
vated by IL-1β. As expected, biochanin A inhibited IL-
1β–stimulated activation of NF-κB p65 and suppressed
the IL-1β–induced degradation of IκB-α, as shown in
Figures 6 and 7.
Gross morphology and histological evaluation
Our in vivo data revealed severe cartilage erosion in all
rabbits treated by ACLT. While rabbits that received
intra-articular injection of biochanin A showed less car-
tilage destruction compared with the vehicle-treated
control group, the difference was not significant. On
histological examination, cartilage specimens from the
vehicle-treated group showed noticeable morphological
changes, including surface irregularities, hypocellularity,and reduction of Safranin-O staining. While a significant
decrease in the severity of cartilage degradation was seen
in biochanin A -treated groups, particularly in the
50 μM group (Figure 8), which was consistent with
histological analyses using the Mankin scoring system
(Table 1).
Effects of biochanin A on MMP-1, −3, −13, and TIMP-1
gene expression
As shown in Figure 9, in vehicle-treated cartilage of OA
rabbits, the relative levels of MMP-1, −3, and −13
mRNA expression were markedly increased, while that
of TIMP-1 was decreased compared to the levels in nor-
mal cartilage. However, MMP-1, −3, and −13 mRNA
levels were downregulated and that of TIMP-1 was up-
regulated in the biochanin-A-treated group in compari-
son with vehicle-treated cartilage.
Discussion
The results of the present study indicated that biochanin
A potently suppressed MMP-1, −3, and −13 expression
Figure 3 Production of MMP-1, −3, −13, and TIMP-1 in cultured supernatant. Production of MMP-1, −3, −13, and TIMP-1 was analyzed by
enzyme-linked immunosorbent assay (ELISA). Data were expressed as means ± standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001,
compared with cells stimulated with IL-1β alone; #P < 0.01, compared with normal chondrocytes. (a), (b), (c), (d) represented as the production
of MMP-1,MMP-3,MMP-13 and TIMP-1 respectively.
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In addition, our results revealed the involvement of NF-
κB in MMP regulation by biochanin A.
Current therapeutic options for OA include Non-
steroidal anti-inflammatory drugs [14] such as cycloo-Figure 4 Effects of biochanin A on protein expression of MMP-1,-3, −
Chondrocytes were incubated for 24 hours with IL-1β or a combination of
were determined by Western blotting. β-actin was used as a loading contrxygenase-2 inhibitors and other agents for pain relief
but these drugs fail to block the progression of the dis-
ease. Apart from this, these clinical agents are associated
with many risks including gastrointestinal [15], car-
diovascular [16] and other adverse events. There is an13, and TIMP-1 in interleukin-1β (IL-1β)–induced chondrocytes.
biochanin A and IL-1β. Protein levels of MMP-1, −3, −13, and TIMP-1
ol in the Western blotting.
Figure 5 Effects of biochanin A on protein expression of MMP-1,-3, −13, and TIMP-1 in interleukin-1β (IL-1β)–induced chondrocytes.
Ratios obtained by normalizing the expressions of MMPs, TIMP-1 IkBa and NFkB to that of beta-actin bands. *P < 0.05, compared with cells
stimulated with IL-1β alone; #P < 0.05, compared with normal chondrocytes.
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natural plants or herbs for the treatment of OA because
they have shown to be clinical efficacy with minimal side
effects, as compared to routine pharmacological strategies.
Biochanin A, an isoflavone derived from red clover, cab-
bage, and alfalfa, has been reported to exert a wide range of
pharmacological effects in different experimental models.Figure 6 Effects of biochanin A on IκB-α degradation and NF-κB activ
pre-treated with various concentrations of biochanin A for 2 h, followed by
Western blotting analysis. Biochanin A suppressed IL-1β-induced degradatiSehdev et al. reported that biochanin A may be a unique
natural anticancer agent that can selectively target cancer
cells and inhibit multiple signaling pathways in HER-2-
positive breast cancer cells [17]. Lee et al. suggested that
biochanin A may play important physiological roles in the
prevention of postmenopausal osteoporosis in osteoblastic
MC3T3-E1 cells [18]. Chen et al. reported that biochanination in IL-1β -induced chondrocytes. Chondrocytes were
co-incubation with IL-1β (10 ng/ml) for 24 h, and harvested for
on of IκB-α and then attenuated IL-1β -stimulated activation of NF-κ B.
Figure 7 Effects of biochanin A on IκB-α degradation and NF-κB activation in IL-1β -induced chondrocytes. Ratios obtained by
normalizing the expressions of IkB-α and NF-kB to that of beta-actin bands. *P < 0.05, compared with cells stimulated with IL-1β alone; #P < 0.05,
compared with normal chondrocytes. The former and latter image represented as the relative expression of NF-κ B p65 and IkB-α respectively.
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damage through inhibition of microglia activation and gen-
eration of proinflammatory factors [19]. In addition, bio-
chanin A was reported to inhibit MMP-9 and MT1-MMP
in human glioblastoma (U87MG) cells. However, little is
known about the effects of biochanin A on osteoarthritic
models or chondrocytes. Recent study showed that bio-
chanin A prevents adipogenesis, enhances osteoblast dif-
ferentiation in mesenchymal stem cells, and has beneficial
regulatory effects in bone formation [20]. In view of the
uncertain effects of biochanin A on osteoarthritis as well
as the close link between biochanin A and MMPs, theFigure 8 Photographs of rabbit articular cartilage stained by Safranin
staining. (b). Vehicle-treated cartilage showed the loss of Safranin O stainin
(d) biochanin A -treated cartilage showed reduction loss of Safranin O stain
the arrow indicate irregular surface. a, b, c, d in Figure 8 represented as no
biochanin A (50 μM)-treated cartilage respectively.present study was performed to explore the potential use
of biochanin A in vitro and in vivo.
Osteoarthritis (OA) is characterized by the loss of the
balance between anabolic and catabolic responses of
stimulated chondrocytes, driven locally by a series of cy-
tokines of which IL-1β is regarded as the major factor
[21]. IL-1β is thought to be one of the most important
catabolic cytokines produced by chondrocytes in OA
[22]. IL-1β is known to be a potent inducer of enzymes,
prostanoids, nitric oxide, and free radicals [23]. More-
over, IL-1β can suppress the synthesis and production of
type II collagen and proteoglycans [24,25]. Upregulation-O. (a). Normal articular cartilage showed no reduction of Safranin
g, the arrow indicates the calcified cartilage and irregular surface. (c),
ing compared with vehicle-treated group (original magnification × 40),
rmal cartilage, vehicle-treated cartilage, biochanin A (5 μM) and
Table 1 Histological score of articular cartilage




Structural changes 3.23 ± 0.31 2.76 ± 0.15 1.8 ± 0.1*
Cellular changes 2.67 ± 0.15 2.27 ± 0.25 1.87 ± 0.15*
Safranin staining 2.9 ± 0.1 2.53 ± 0.21 1.94 ± 0.15*
Total score 8.8 ± 0.53 7.57 ± 0.40* 5.6 ± 0.26*
Values are the mean ± SD. *p < 0.05 compared with vehicle group.
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deed, increased levels of IL-1β have been detected in the
synovial fluid of patients with OA [26,27]. Our data con-
firmed that IL-1β increased the expression levels of
MMPs (including MMP-1, −3, and −13) and decreased
the expression of TIMP-1 in chondrocytes, consistent
with previous reports [28,29].
MMPs comprise a family of enzymes that facilitate
extracellular matrix (ECM) turnover and breakdown. All
members of the MMP family have been linked to disease
development, notably arthritis, cancer metastasis, chronic
inflammation, and neurological disorders [30]. Among all
MMPs, MMP-13 has been reported to play a central role
in the progression of OA due to its potent proteolytic ef-
fects on collagen II, the main component of the ECM. TheFigure 9 Relative gene expression in articular cartilage. The relative gene
quantitative real-time PCR. Data were presented as means ± standard deviatio
cartilage. (a), (b), (c), (d) represented as the relative gene expression of MMP-specialized role of MMP-13 in bone development and dis-
ease progression has made it an attractive target for select-
ive MMP-13 inhibitors as therapeutic compounds [31,32].
MMP-1 is a secreted enzyme and has wide substrate spe-
cificity for degradation of collagens, aggrecan, versican,
serpins, and tenascin-C [33]. The substrate specificity
of MMP-3 is also broad; MMP-3 has been shown to
break down a number of ECM proteins, including fibro-
nectin, laminin, denatured collagens, and proteoglycans.
In addition to ECM degradation, MMP-3 is involved in
the activation cascades of MMP-13 and gelatinases. Since
MMP-1 and MMP-3 play vital roles in ECM turnover,
their regulation has been suggested to be useful in the
treatment of OA [34]. Interestingly, our results demon-
strated that the upregulated MMP-1, −3, and −13 expres-
sion in IL-1β-stimulated chondrocytes were all markedly
decreased by biochanin A in a dose-dependent manner.
In view of the effects of biochanin A on MMP-2 and
MMP-9 as reported previously [10], we also detected
the expresson and production of MMP-2 and MMP-9.
However, the results were not statistically significant.
TIMPs, the endogenous regulators of MMPs, play im-
portant roles in maintaining homoeostasis with MMPs.
Imbalance between MMPs and TIMPs is a salient fea-
ture during OA progression, leading to disruption ofexpression of MMP-1, −3, −13 and TIMP-1 was calculated by using
n (SD). *P < 0.05, **P < 0.01, ***P < 0.001, compared with vehicle-treated
1,MMP-3,MMP-13 and TIMP-1 respectively.
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ation. Since the activities of MMPs can be inhibited by
TIMPs, we investigated the effects of biochanin A on
TIMP-1 expression; our results suggested upregulation
of TIMP-1 by biochanin A in IL-1β–stimulated chon-
drocytes. Hence, we speculated that biochanin A may
exert its chondroprotective effects by regulating the ex-
pression and activity of MMPs and TIMPs.
The NF-κB signaling pathway is known to play a vital
role in OA [35,36]. In the progression of OA, NF-κB
transcriptional factors can be triggered by a number of
stimuli, such as cytokines, excessive mechanical stress
and degradation products of ECM. Activated NF-κB reg-
ulates several enzymes involved in matrix degradation,
including MMP-1, −3, and −13 [37]. In general, NF-κB
p65 is associated with IκB-α in an inactive form in the
cytoplasm. Following IκB-α phosphorylation by stimuli,
such as IL-1β, the nuclear localization signal is no longer
masked, leading to translocation of NF-κB p65 to the
nucleus [38]. Since biochanin A inhibited the NF-κB ac-
tivation pathway in other experimental models [9,39],
we investigated the involvement of the NF-κB signaling
pathway in MMP modulation by biochanin A in chon-
drocytes. In this study, we showed that biochanin A
inhibited IκB-α degradation and then attenuated the ac-
tivation of NF-κB p65. However, further studies of the
mechanism underlying the effect of biochanin A in the
treatment of OA are required.
In addition, we used the ACLT (anterior cruciate liga-
ment transection) model to assess the effects of biochanin
A in vivo, which has proven to be effective and reliable
[40,41]. Pickarski M et al. reported that matrix degradation
and up-regulation of MMPs were obviously observed in
the surgically-induced models of osteoarthritis [42]. Similar
findings were reported by Li X et al., they found that
MMP-13 was strikingly up-regulated in ACLT-induced OA
[43]. Consistent with our in vitro data, the results of
the in vivo study showed that the levels of MMP-1, −3,
and −13 expression were decreased, while that of TIMP-1
was increased, in biochanin-A-treated cartilage compared
with vehicle-treated controls. Moreover, we demonstrated
that intra-articular injection of biochanin A ameliorated
cartilage degradation during the progression of OA. Taken
together, these findings confirm the potential value of bio-
chanin A in the treatment of OA.
Conclusions
In conclusion, we demonstrated at both the mRNA and
protein levels that biochanin A inhibited the expression of
MMP-1, −3, and −13 and increased the expression of
TIMP-1, all of which are classic biomarkers of inflamma-
tion and cartilage degradation in OA. Our study provided
strong evidence that these protective effects of biochanin
A are mediated at least in part via inhibition of the NF-κBpathway. Taken together, these findings indicate that bio-
chanin A exerts anticatabolic effects in the progression of
OA and may reduce the rate of cartilage degradation.
Therefore, biochanin A may be useful for the treatment
and prevention of OA.
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